Thoratec pumped up by Medicare LVAD (left ventricular assist device) coverage decision
This article was originally published in Clinica
Executive Summary
In a victory for Thoratec, Medicare has announced that it will cover left ventricular assist devices (LVADs) to treat beneficiaries with end-stage heart failure and, moreover, will raise the rates that hospitals receive for implanting the devices by about 25%.